Psoriatic Arthritis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Psoriatic Arthritis – Pipeline Review, H2 2019’, provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis

– The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects

– The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“3SBio Inc

AbbVie Inc

AbGenomics International Inc

Aclaris Therapeutics Inc

Agragen LLC

Akeso Biopharma Inc

Alpine Immune Sciences Inc

Alvotech ehf

Amgen Inc

Bio-Thera Solutions Ltd


Biocon Ltd

BioXpress Therapeutics SA

Bristol-Myers Squibb Co

Celltrion Inc

DNX Biopharmaceuticals Inc

FYB202 GmbH & Co KG

Galapagos NV

Hengenix Biotech Inc

Immunwork Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Johnson & Johnson

Kangpu Biopharmaceuticals Ltd

Kv1.3 Therapeutics

Lupin Ltd

Machavert Pharmaceuticals LLC

Mycenax Biotech Inc

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Novartis AG

Pfizer Inc


Polpharma Biologics

RNAx Ltd

Shandong Boan Biological Technology Co Ltd

Shanghai Junshi Bioscience Co Ltd

Siam Bioscience Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

SynAct Pharma AB


Xbrane Biopharma AB”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Psoriatic Arthritis Overview 6

Psoriatic Arthritis Therapeutics Development 7

Psoriatic Arthritis Therapeutics Assessment 15

Psoriatic Arthritis Companies Involved in Therapeutics Development 23

Psoriatic Arthritis Drug Profiles 39

Psoriatic Arthritis Dormant Projects 217

Psoriatic Arthritis Discontinued Products 219

Psoriatic Arthritis Product Development Milestones 220

Appendix 233

List of Tables

“List of Tables

Number of Products under Development for Psoriatic Arthritis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Psoriatic Arthritis – Dormant Projects, H2 2019

Psoriatic Arthritis – Dormant Projects, H2 2019 (Contd..1), H2 2019

Psoriatic Arthritis – Dormant Projects, H2 2019 (Contd..2), H2 2019

Psoriatic Arthritis – Discontinued Products, H2 2019”


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports